NCT07259590 A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
| NCT ID | NCT07259590 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Condition | Advanced Solid Tumors Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2025-10-21 |
| Primary Completion | 2027-07 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To evaluate the safety/tolerability and pharmacokinetic (PK) characteristics of GFH375 in combination with cetuximab or AG in participants with solid tumors, and to explore the efficacy of the combination therapy. Phase II: To evaluate the efficacy, safety/tolerability and PK characteristics of the combination therapy, and to explore the correlation between bio-marker and clinical efficacy.
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily participate in the study and sign the informed consent form. 2. Participants receiving Regimen A must be ≥ 18 years old when signing the informed consent form, and participants receiving Arm B must be 18 - 75 years old. 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation. 4. Failed standard systemic treatment, or intolerant to standard treatment, or unsuitable for standard treatment, or no standard treatment available. 5. At least one measurable lesions according to RECIST v1.1 6. Participants receiving Regimen A must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 - 2; participants receiving Regimen B must have an ECOG PS score of 0 - 1. 7. Have sufficient organ function. Exclusion Criteria: 1. Symptomatic brain metastasis, leptomeningeal metastasis, spinal cord compression, or primary brain tumor. 2. Presence of known coexisting other cancer
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.